Meeting the demand for fertility services: the present and future of reproductive endocrinology and infertility in the United States.

Autor:	Hariton E; Reproductive Science Center of the San Franisco Bay Area, San Francisco, California., Alvero R; Fertility and Reproductive Health, Lucille Packard Children's Hospital, Sunnyvale, California; Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California. Electronic address: ralvero@stanford.edu., Hill MJ; National Institutes of Health, National Institute for Child Health and Human Development, Program in Reproductive and Adult Endocrinology, Bethesda, Maryland., Mersereau JE; Shady Grove Fertility, Raleigh, North Carolina., Perman S; Shady Grove Fertility, Washington, District of Columbia; Shady Grove Fertility, Columbia, Maryland., Sable D; Special Situations Life Sciences Fund and Department of Biological Sciences, Columbia University, New York, New York., Wang F; Lucile Packard Children's Hospital/Stanford Children's Health and Stanford Fertility and Reproductive Health, Sunnyvale, California., Adamson GD; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, ACF, Stanford University, Stanford, California., Coutifaris C; Division of Reproductive Endocrinology and Infertility, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Craig LB; Section of Reproductive Endocrinology and Infertility, Department of Obstetrics & Gynecology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma., Hosseinzadeh P; Section of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Johns Hopkins University, Baltimore, Maryland., Imudia AN; Department of Obstetrics and Gynecology, University of South Florida Morsani College of Medicine, Tampa, Florida., Johnstone EB; Division of Reproductive Endocrinology and Infertility, University of Utah, Salt Lake City, Utah., Lathi RB; Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California., Lin PC; Seattle Reproductive Medicine, Seattle, Washington; Seattle Reproductive Medicine, Bellevue, Washington., Marsh EE; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan., Munch M; Department of Obstetrics and Gynecology, Pennsylvania State University Health, York, Pennsylvania., Richard-Davis G; Department of Obstetrics and Gynecology, Reproductive Endocrinology and Infertility, University of Arkansas, Little Rock, Arkansas., Roth LW; Shady Grove Fertility, Rockville, Maryland., Schutt AK; Texas Fertility Center, Austin, Texas; Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas., Thornton K; Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston; Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston; Boston IVF, Waltham, Massachusetts., Verrilli L; Division of Reproductive Endocrinology and Infertility, University of Utah, Salt Lake City, Utah., Weinerman RS; Department of Obstetrics and Gynecology, Case Western Reserve University School of Medicine, Cleveland, Ohio., Young SL; Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Duke University, Durham, North Carolina., Devine K; National Institutes of Health, National Institute for Child Health and Human Development, Program in Reproductive and Adult Endocrinology, Bethesda, Maryland; Shady Grove Fertility, Washington, District of Columbia; Departments of Obstetrics and Gynecology, Georgetown University and George Washington University, Washington, DC.
Jazyk:	angličtina
Zdroj:	Fertility and sterility [Fertil Steril] 2023 Oct; Vol. 120 (4), pp. 755-766. Date of Electronic Publication: 2023 Sep 04.
DOI:	10.1016/j.fertnstert.2023.08.019
Abstrakt:	The field of reproductive endocrinology and infertility (REI) is at a crossroads; there is a mismatch between demand for reproductive endocrinology, infertility and assisted reproductive technology (ART) services, and availability of care. This document's focus is to provide data justifying the critical need for increased provision of fertility services in the United States now and into the future, offer approaches to rectify the developing physician shortage problem, and suggest a framework for the discussion on how to meet that increase in demand. The Society of REI recommend the following: 1. Our field should aggressively explore and implement courses of action to increase the number of qualified, highly trained REI physicians trained annually. We recommend efforts to increase the number of REI fellowships and the size complement of existing fellowships be prioritized where possible. These courses of action include: a. Increase the number of REI fellowship training programs. b. Increase the number of fellows trained at current REI fellowship programs. c. The pros and cons of a 2-year focused clinical fellowship track for fellows interested primarily in ART practice were extensively explored. We do not recommend shortening the REI fellowship to 2 years at this time, because efforts should be focused on increasing the number of fellowship training slots (1a and b). 2. It is recommended that the field aggressively implements courses of action to increase the number of and appropriate usage of non-REI providers to increase clinical efficiency under appropriate board-certified REI physician supervision. 3. Automating processes through technologic improvements can free providers at all levels to practice at the top of their license. Competing Interests: Declaration of interests G.D.A. reports consulting fees from LabCorp; Advisor, World Health Organization (WHO); Chair, International Committee for Monitoring Assisted Reproductive Technology (ICMART); Past Chair Member, International Federation of Gynecology and Obstetrics (FIGO) Committee on Reproductive Endocrinology and Infertility; President, World Endometriosis Research Foundation (WERF); Non-voting Board Observer, International Federation of Fertility Societies; Advanced Reproductive Care, Inc. (DBAARC Fertility): Founder and CEO outside the submitted work. C.C. reports funding from NICHD P50-HD068157 and NICHD K12-HD001256; travel support from Institutional (UPenn) professional-related account; American Gynecological and Obstetrical Society (Member of the Board and President 2022-23) outside the submitted work. L.B.C. reports funding from Ferring Pharmaceuticals site investigator, Presbyterian Health Foundation, and R01HD100305 Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH/NICHD; travel support from Ferring Pharmaceuticals; Patent application Methods and compositions for treating diseases and conditions associated with gonadotropin releasing hormone receptor; leadership roles – OU Health Partners Board of Directors, American Board of Obstetrics & Gynecology division of Reproductive Endocrinology and Infertility outside the submitted work. K.D. reports consulting fees from Bludiagnostics (Amazon-affiliated women’s health product), Medscape, and Presagen; honoraria from ASRM, UCSD, and Medscape; travel support from ASRM, SART, and Granata Bio; SREI Research chair, SART Quality Assurance Chair outside the submitted work. E.H. reports stock options as medial advisor for Alife Health and Cercle AI outside the submitted work. M.J.H. reports Research Advisor for Thread Robotics outside the submitted work. S.P. is chair-elect for the ASRM Advanced Practice Provider Professional Group outside the submitted work. D.S. reports leadership role Hamilton Thorne Ltd and Celmatix Inc.; stock options Hamilton Thorne Ltd; manages investment funds that invest in the IVF industry, with ownership in Cooper Companies Inc., CryoPort Inc., Hamilton Thorne Ltd, INVO Bioscience Inc., Jinxin Fertility Group Ltd, Monash IVF Group Ltd, Progyny Inc., Virtus Health Ltd, Vitrolife AB, Celmatix Inc., MedAnswers, Oova, and TMRW Life Sciences outside the submitted work. K.T. reports Advisory Board: fee for travel and participation on advisory board form LabCorp; honoraria from Midwest Fertility Society; travel support ASRM Board of Directors; Data Safety Monitoring Board – Yale Center statistics Science is the Data Coordinating Center for the PREGnant and Friend Randomized trials; member ASRM Board of Directors; stockholder Pharmaceutical Contracting Alliance outside the submitted work. L.V. physician advisory board at ALife outside the submitted work. S.L.Y. reports licensed intellectual property to CiceroDX for the ReceptivaDx clinical test; author for an UpToDate chapter on endometriosis and infertility outside the submitted work. R.A. has nothing to disclose. J.E.M. has nothing to disclose. F.W. has nothing to disclose. P.H. has nothing to disclose. A.N.I. has nothing to disclose. E.B.J. has nothing to disclose. R.B.L. has nothing to disclose. P.C.L. has nothing to disclose. E.E.M. has nothing to disclose. M.M. has nothing to disclose. G.R-D. has nothing to disclose. L.W.R. has nothing to disclose. A.K.S. has nothing to disclose. R.S.W. has nothing to disclose. (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu